Cabozantinib + BEVACIZUMAB + ATEZOLIZUMAB + EMACTUZUMAB + RUCAPARIB + SIMLUKAFUSP ALFA + ALECTINIB

1 treatment and condition followed through the public trial records. Not medical advice. How a status is set

Treatments and conditions

Cabozantinib + BEVACIZUMAB + ATEZOLIZUMAB + EMACTUZUMAB + RUCAPARIB + SIMLUKAFUSP ALFA + ALECTINIB
Treatment and conditionWhere it standsTrials
Cabozantinib + BEVACIZUMAB + ATEZOLIZUMAB + EMACTUZUMAB + RUCAPARIB + SIMLUKAFUSP ALFA + ALECTINIB for neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1